Teva Pharmaceutical Industries Ltd (TEVA) Stock Price & Analysis
Teva Pharmaceutical Industries Ltd (TEVA) fell 1.19% to USD 30.81 as of July 25, 2026 at 01:47 UTC, according to Nexqual real-time market data.
TEVA last closed at USD 31.18; the session ranged USD 30.77–31.86 on volume of 2,735,096 shares. Market capitalization is $35.88B, with a 52-week range of USD 14.99–37.35 (NYQ). Source: Nexqual, July 25, 2026 at 01:47 UTC.
Key Statistics (as of July 25, 2026 at 01:47 UTC)
| Price | USD 30.81 |
|---|---|
| Change | ▼ 1.19% (down) |
| Previous Close | USD 31.18 |
| Open | USD 31.23 |
| Day Range | USD 30.77 – 31.86 |
| 52-Week Range | USD 14.99 – 37.35 |
| Volume | 2,735,096 shares |
| Market Cap | $35.88B |
| Exchange | NYQ |
Technical Analysis (TEVA)
Nexqual's technical model rates TEVA "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:47 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.73 (neutral) |
| vs SMA50 | Below (USD 33.42) |
| MACD | -0.75 (negative) |
Analyst Ratings (TEVA)
Wall Street analysts rate TEVA "Strong Buy" based on 10 analysts, with a mean price target of USD 40.9 (range USD 33–50), per Nexqual as of July 25, 2026 at 01:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 40.9 |
| High Target | USD 50 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (TEVA)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.11 |
| Revenue Estimate | $4.04B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.53 vs est 0.46 ▲ beat |
| 2025-12-31 | USD 0.96 vs est 0.64 ▲ beat |
| 2025-09-30 | USD 0.78 vs est 0.67 ▲ beat |
| 2025-06-30 | USD 0.66 vs est 0.62 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financials & Fundamentals (TEVA)
| Total Revenue | $17.35B |
|---|---|
| Revenue Growth (YoY) | +2.30% |
| Gross Margin | +52.06% |
| Operating Margin | +19.16% |
| Profit Margin | +9.02% |
| ROE | +21.60% |
| Debt / Equity | 205.6 |
| Current Ratio | 1.01 |
| Total Cash | $3.74B |
| Total Debt | $16.92B |
| Free Cash Flow | $2.61B |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financial Health Score (TEVA)
Nexqual rates Teva Pharmaceutical Industries Ltd's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:47 UTC.
| Growth | Mixed — Revenue +4.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 19% |
| Balance Sheet | Weak — $3.74B cash vs $16.9B debt |
| Cash Flow | Strong — FCF $2.61B, 15% margin |
| Efficiency | Strong — ROE 22%, ROA 6.4% |
Ownership (TEVA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +63.34% |
| Shares Outstanding | 1.16B |
| Float | 1.08B |
| Short % of Float | +2.77% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Leadership (TEVA)
Teva Pharmaceutical Industries Ltd is led by Richard D. Francis (age 57), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:47 UTC.
| President, CEO & Director | Richard D. Francis (age 57) |
|---|---|
| Executive VP & CFO | Eliyahu Sharon Kalif (age 51) |
| Executive Vice President of Business Development | Evan Lippman (age 55) |
| Executive Vice President of Global Operations | Matthew Shields (age 50) |
| Senior Vice President of Investor Relations & Competitive Intelligence | Christopher J. Stevo |
Major Backers & Investors (TEVA)
Notable institutional backers of Teva Pharmaceutical Industries Ltd include Harel Insurance Investments & Financial Services Ltd., Phoenix Financial Ltd., WCM Investment Management, LLC, according to Nexqual as of July 25, 2026 at 01:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Harel Insurance Investments & Financial Services Ltd. | 3.95% |
| Phoenix Financial Ltd. | 3.67% |
| WCM Investment Management, LLC | 3.51% |
| Menora Mivtachim Holdings Ltd. | 3.4% |
| Clal Insurance Enterprises Holdings Ltd | 3.3% |
| Migdal Insurance & Financial Holdings Ltd. | 3.25% |
| FMR, LLC | 2.84% |
| Lingotto Investment Management LLP | 2.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.99% |
| State Street | 1.53% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
From Teva Pharmaceutical Industries Ltd's Latest SEC 10-K Filing (filed 2026-02-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors or we may not be able to maintain the confidentiality of information relating to such products.
- If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our intellectual property rights, our results of operations, financial condition and cash flows could suffer.
- Any manipulation, theft, loss and/or fraudulent use of customer, employee or proprietary data as a result of a cyber-attack targeting us or one of our third-party service providers could subject us to significant litigation, liability and costs, as well as adversely impact our reputation with customers and regulators.
- We may not be successful in seeking or consummating appropriate opportunities to enable us to execute on our business strategy.
Partnerships
- In 2016, we paid a monetary fine for FCPA violations and entered into a three-year deferred prosecution agreement with the DOJ, which included retaining an independent compliance monitor.
- In addition, we, or the partners with which we may enter into licensing or other collaboration agreements, may not be able to perform effectively under such agreements, impairing our ability to monetize opportunities related to them.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GILD | Gilead Sciences, Inc. | USD 129.31 | ▼ 0.79% |
| BIIB | Biogen Inc. | USD 202.19 | ▲ 2.25% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| NVS | Novartis AG | USD 155.01 | ▲ 1.26% |
| AMGN | Amgen Inc. | USD 376.04 | ▲ 2.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:47 UTC. This page is informational and not investment advice.